Literature DB >> 25618316

Short-term mortality of adult inpatients with community-acquired pneumonia: external validation of a modified CURB-65 score.

Marc Andre Pflug1, Timothy Tiutan2, Thomas Wesemann3, Harald Nüllmann3, Hans Jürgen Heppner4, Ludger Pientka3, Ulrich Thiem5.   

Abstract

OBJECTIVE: The management of community-acquired pneumonia (CAP) continues to be a challenge, especially in older people. To enable better risk stratification, a variation of the severity scores CRB-65 and CURB-65, called CURB-age, has been suggested. We compared the association between risk groups as defined by the scores and 30-day mortality for a cohort of mainly older inpatients with CAP.
METHODS: We retrospectively analysed data from the CAP database from the years 2005 to 2009 of a single centre in Herne, Germany. Patient characteristics, criteria values within the severity scores CURB-65, CRB-65 and CURB-age, and 30-day mortality were assessed. We compared the association between score points and score-defined risk groups and mortality. Sensitivity and specificity with corresponding 95% CIs were calculated, and receiver operating characteristic (ROC) curve analysis was performed.
RESULTS: Data from 559 patients were analysed (mean age 74.1 years, 55.3% male). Mortality at day 30 was 10.9%. CURB-age included more patients in the low-risk category than CRB-65 (195 vs 89), and the patient group had a lower mortality (2.6% vs 3.4%). When compared with CURB-65, CURB-age included slightly fewer patients (195 vs 214) with lower mortality (2.6% vs 4.2%). CURB-age sorted the most patients who died within 30 days into the high-risk CAP group (CURB-age, 32; CURB-65, 28; CRB-65, 9), which had the highest mortality (CURB-age, 26.4%; CURB-65, 19.4%; CRB-65, 21.4%). Advantages of CURB-age categories were depicted through ROC curve analysis (area under the curve 0.73 (95% CI 0.67 to 0.79) for CURB-age categories, 0.67 (95% CI 0.60 to 0.74) for CURB-65 categories, and 0.59 (95% CI 0.52 to 0.66) for CRB-65 categories).
CONCLUSIONS: In comparison with CRB-65 and CURB-65, risk stratification as defined by CURB-age showed the closest association with 30-day mortality in our sample. Further prospective studies are needed to assess the potential of CURB-age for better risk prediction, especially in older patients with CAP. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Keywords:  CURB-65; CURB-age; INFECTIOUS DISEASES; community-acquired pneumonia; risk prediction

Mesh:

Year:  2015        PMID: 25618316     DOI: 10.1136/postgradmedj-2014-132802

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  4 in total

Review 1.  Meta-analysis of Calibration, Discrimination, and Stratum-Specific Likelihood Ratios for the CRB-65 Score.

Authors:  Mark H Ebell; Mary E Walsh; Tom Fahey; Maggie Kearney; Christian Marchello
Journal:  J Gen Intern Med       Date:  2019-04-16       Impact factor: 5.128

2.  Real-time electronic health record mortality prediction during the COVID-19 pandemic: a prospective cohort study.

Authors:  Peter D Sottile; David Albers; Peter E DeWitt; Seth Russell; J N Stroh; David P Kao; Bonnie Adrian; Matthew E Levine; Ryan Mooney; Lenny Larchick; Jean S Kutner; Matthew K Wynia; Jeffrey J Glasheen; Tellen D Bennett
Journal:  J Am Med Inform Assoc       Date:  2021-10-12       Impact factor: 4.497

3.  Population-based incidence and mortality of community-acquired pneumonia in Germany.

Authors:  Christian Theilacker; Ralf Sprenger; Friedhelm Leverkus; Jochen Walker; Dennis Häckl; Christof von Eiff; Julia Schiffner-Rohe
Journal:  PLoS One       Date:  2021-06-15       Impact factor: 3.240

4.  Expanded A-DROP Score: A New Scoring System for the Prediction of Mortality in Hospitalized Patients with Community-acquired Pneumonia.

Authors:  June Hong Ahn; Eun Young Choi
Journal:  Sci Rep       Date:  2018-10-01       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.